Results 11 to 20 of about 181,580 (299)

Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen [PDF]

Scientific Reports, 2022
The appropriate timing of treatment cessation after treat and extend (TAE) regimen for age-related macular degeneration has not been established. This study aimed to investigate the incidence and risk factors of recurrence after cessation of the TAE ...
Yuki Hirata, Akio Oishi, Yuki Maekawa, Eiko Tsuiki, Akira Machida, Junko Kurihara, Takashi Kitaoka   +6 more
doaj   +4 more sources

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration [PDF]

International Journal of Retina and Vitreous, 2021
Purpose To investigate the visual and anatomical outcomes associated with treat-and-extend (TAE) regimen of intravitreal (IVT) aflibercept in eyes with treatment naïve neovascular age-related macular degeneration (nvAMD).
Mohamed Kamel Soliman, Nicolas Tuli, Thomas K. Lee, William A. Britton, Raman Tuli   +4 more
doaj   +2 more sources

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration [PDF]

International Journal of Retina and Vitreous, 2021
Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin, Asem Mohamed, Cristian Munteanu, Isabel Weinstein, Achim Langenbucher, Berthold Seitz, Shady Suffo   +6 more
doaj   +2 more sources

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice [PDF]

International Journal of Retina and Vitreous
Purpose To evaluate the clinical outcomes of the switch to faricimab in a treat-and-extend (T&E) regimen patients with neovascular age-related macular degeneration (nAMD).
Jorge Ruiz-Medrano, Iulia Pana, María García-Zamora, Ignacio Flores-Moreno, Mariluz Puertas, José Mª Ruiz-Moreno   +5 more
doaj   +2 more sources

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result [PDF]

Pharmaceuticals, 2023
We aimed to investigate whether a treat-and-extend regimen of intravitreal brolucizumab (6.0 mg/0.05 mL) is effective for eyes with exudative age-related macular degeneration (AMD) refractory to aflibercept for 12 months.
Wataru Kikushima, Yoichi Sakurada, Yoshiko Fukuda, Mio Matsubara, Yumi Kotoda, Atsushi Sugiyama, Kenji Kashiwagi   +6 more
doaj   +2 more sources

Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice [PDF]

Ophthalmology and Therapy
Introduction Anti-vascular endothelial growth factor (VEGF) is generally given using pro re nata or “treat-and-extend” (T&E) regimens for neovascular age-related macular degeneration (nAMD).
Eloi Debourdeau, Helene Beylerian, Vuong Nguyen, Daniel Barthelmes, Mark Gillies, Pierre Henry Gabrielle, Stela Vujosevic, Louise Otoole, Martin Puzo, Catherine Creuzot-Garcher, Benjamin Wolff, Vincent Daien, The Fight Retinal Blindness! Study Group   +12 more
doaj   +2 more sources

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients [PDF]

Vision, 2019
Treat and extend (T&E) is a standard treatment regimen for treating neovascular age-related macular degeneration (nAMD) with anti-vascular endothelial growth factors (anti-VEGFs), but the treatment intervals attained are not well documented.
Adrian Skelly, Vladimir Bezlyak, Gerald Liew, Elisabeth Kap, Alexandros Sagkriotis   +4 more
doaj   +3 more sources

Five-year outcome of aflibercept intravitreal injection in naïve patients with neovascular age-related macular degeneration using a modified treat-and-extend regimen: Results from a prospective observational study [PDF]

Taiwan Journal of Ophthalmology, 2023
PURPOSE: The purpose is to study the 5-year results of aflibercept monotherapy using an individualized regimen in naïve patients with neovascular AMD (nAMD). MATERIALS AND METHODS: This is a prospective observational study including naïve nAMD patients
Jarret Charles, TRAN Thi Ha Chau
doaj   +2 more sources

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group [PDF]

Clinical Ophthalmology, 2018
Winfried Amoaku,1 Konstantinos Balaskas,2,3 Tomas Cudrnak,4 Louise Downey,5 Markus Groppe,6 Sajjad Mahmood,7 Hemal Mehta,8 Quresh Mohamed,9 Bushra Mushtaq,10 Philip Severn,11 Athanasios Vardarinos,12 Yit Yang,13 Saad Younis14 1Academic Ophthalmology ...
Amoaku W, Balaskas K, Cudrnak T, Downey L, Groppe M, Mahmood S, Mehta H, Mohamed Q, Mushtaq B, Severn P, Vardarinos A, Yang Y, Younis S   +12 more
doaj   +2 more sources

Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study [PDF]

BMC Ophthalmology
Background to analyze, at one year, the efficacy and safety of treat-and-extend (T&E) intravitreal (IV) Brolucizumab in patients affected by macular neovascularization (MNV).
Francesco Faraldi, Carlo Alessandro Lavia, Marco Nassisi, Raphael Kilian, Clara Rizzo, Maria Cristina Savastano, Stanislao Rizzo, Fabrizio Giansanti, Daniela Bacherini   +8 more
doaj   +2 more sources